In addition, research on major depressive disorder (MDD) revealed that C-reactive protein (CRP) could serve as a marker of neuroinflammation and peripheral inflammation and is well-suited for guiding immunotherapy targeting inflammatory cytokines such as TNF-α and IL-6 in the patient with MDD (Felger et al., 2020). This evidence concerns the gene IL6 and major depressive disorder.